Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
Puntos clave
Advances in SGLT2 inhibitors and GLP-1 receptor agonists improve outcomes for type 2 diabetes patients.
Review covers a decade of developments in cardiovascular disease related to these therapies.
This comprehensive review summarizes the progress made over ten years in managing type 2 diabetes.
Findings indicate significant improvements in treatment options for cardiovascular disease patients with type 2 diabetes.
Resumen
Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review | Synapse
Cite This Study
Aristizábal-Colorado et al. (Wed,) studied this question.